论文部分内容阅读
目的评价重组人脑钠尿肽(rhBNP)治疗慢性心力衰竭(CHF)的疗效。方法CHF患者53例,分为rhBNP组23例和对照组30例。观察两组用药前后右房压(RAP)、肺毛细血管楔嵌压(PCWP)、肺动脉压(PAP)、心脏指数(CI)、血浆去甲肾上腺素(NE)、血管紧张素Ⅱ(AngⅡ)及醛固酮(Ald)的变化。结果rhBNP在降低RAP,PCWP,PAP,NE,AngⅡ及Ald等指标方面与对照组和本组治疗前比较均有统计学差异。对CI、血钠、血钾无明显影响。无明显不良反应。结论rhBNP可改善CHF患者血流动力学状况,拮抗NE,AngⅡ,Ald的过度激活,较为安全。
Objective To evaluate the efficacy of recombinant human brain natriuretic peptide (rhBNP) in the treatment of chronic heart failure (CHF). Methods Fifty-three CHF patients were divided into rhBNP group (n = 23) and control group (n = 30). Right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP), cardiac index (CI), plasma NE and angiotensin Ⅱ were observed before and after treatment. And aldosterone (Ald) changes. Results Compared with control group and this group, rhBNP had statistical significance in reducing the indexes of RAP, PCWP, PAP, NE, AngⅡ and Ald. Right CI, serum sodium, potassium had no significant effect. No obvious adverse reactions. Conclusion rhBNP can improve the hemodynamic status of CHF patients, and antagonize the over-activation of NE, AngⅡ and Ald, which is safe.